SUISSE LIFE SCIENCE
INVESTOR RELATIONS

Suisse Life Science Group is a digital biological intelligence group headquartered in London with companies in Switzerland and in Brazil. Suisse Life Science is focused on creating, developing and managing Lifestyle Medicine and Life-Changing Digital Applications (iDDNA® technology) to maximize human performance:

  • Technology and operational platforms to provide personalized digital health tools and advanced, tailor-made anti-aging treatments under the compounding pharmacy framework with a very short time to market.
  • Experiential online platform integrated with the most popular wearables and health & wellness toolkits available on the market.
  • Integrated e-business B2B platform to connect providers in the value chain to support proximity delivery points after scaling up.
  • Advanced genetics, life science and bio-informatics expertise, ready to plug in any other biologically relevant marker with an omni channel approach (DTC, PROFESSIONAL, RESEARCH).
CUSTOMIZABLE ON BIOLOGICALLY RELEVANT MARKERS (MICROBIOME, BLOOD, HORMONE)

Every two years, the world’s database doubles and every three years, health information also doubles. By 2020, global healthcare data will double every three days with 80% of the data being unstructured, with no clear relationship.

To truly get the results consumers deserve, health & wellness data needs to translate into accurate and actionable recommendations for both consumers and professionals.

Suisse Life Science Group’s IP includes:

Proprietary genetic panels, methods and life science knowledge base

Patent-pending proprietary bioinformatics algorithms

Trademarks and patents

For example, the following Swiss patent filings:

  • Methods for generating and screening metabolic and genetic diversity to prevent aging-related diseases
  • Bioinformatics data mining platform for targeted knowledge discovery and precision medicine
  • Metabolic matching-diet and dynamic food environment reorganization for active weight management and disease prevention
  • Methods for identifying a subject’s macronutrient sensitivity
  • Methods for identifying a subject’s micronutrient sensitivity
  • Multi-tier approach and integrated genomic services to prevent celiac disease and genetic food sensitivities
  • Methods and algorithms to generate and adapt in real-time a healthy weight management plan (macronutrient ratio, micronutrient needs, preventivi nutrition, metabolic exercise needs, epigenetic chrono-nutrition) to the subjects biological age and lifestyle.

SUISSE LIFE SCIENCE PROPRIETARY PROCESS

Suisse Life Science manages its services on a proprietary custom genotyping panel designed on Affymetrix Precision Medicine v2 DTC Axiom Array.

Suisse Life Science’s genetic panel is currently the broadest lifestyle genetic panel in the world and the most comprehensive array focused only on qualitative interpretation of the root causes of aging.

The Affymetrix Precision Medicine (PM) array technology platform incorporates multiple content categories, including a genome wide association study (GWAS) panel of markers for genome wide coverage in major ethnic groups, rare coding SNPs and indels for exome analysis, pharmacogenomic markers, eQTLs, and newly discovered loss-of-function variants, including sequence insertions and deletions from recent exome sequencing initiatives, totaling ~820,000/975,000 SNPs.

Affymetrix is now part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries.

Suisse Life Science’s custom chip was designed according to our R&D including:

  • 956 SNPs (733 validated, 223 de-novo human markers on the array on at least one strand (both where possible), tiled at 4 replicates (per strand)
  • 175 VNTR human markers.

Those genetic markers are individually interpreted according to

  • Genetic and metabolic published cross-references
  • Individual lifestyle
  • Real-time detected environmental conditions
  • Individual goals

Generating a personal Genetic Positioning System (GPS).

Suisse Life Science’s GPS methods are grounded on published metabolic associations and scientific aging theories.

To run on the GeneTitan the custom Affymetrix Precision Medicine v2 DTC (DTC) Axiom Array, DNA is previously extracted from the samples using the Thermo King-Fisher Flex DNA extraction instrument utilizing Qiagen chemistry.

SUISSE LIFE SCIENCE GROUP OF COMPANIES

SUISSE LIFE SCIENCE S.A.
Lugano - Switzerland
100%
SUISSE LIFE SCIENCE GROUP
London - UK
51%
SUISSE LIFE SCIENCE BIOTECNOLOGIA Ltda.
São Paulo - Brazil

RELEVANT INVESTORS

Tamburi
Investment
Partners S.p.A.
2.36%
DEEPMIND Ventures Ltd.
49.56%
Bonsai Capital
Ltd.
18.00%
GDTRE S.r.l.
17.30%
Private
Investors
7.78%
Ron Valk
5.00%
Suisse Life Science Group ShareholdersNationality
DEEPMIND Ventures Ltd.49.56%MT
Bonsai Capital Ltd.18.00%UK
GDTRE S.r.l.17.30%IT
Private Investors7.78%UK
Ron Valk5.00%UK
Tamburi Investment Partners S.p.A.2.36%IT

DEEPMIND Ventures is an investment company representing Suisse Life Science founders and top management.

Bonsai Capital Ltd. is a principal investor in early-stage Life Science companies, focused on start ups developing medicines, platform technologies, and diagnostics, addressing broad disease and condition areas

GDTRE Srl is an Italian private office and prime investor in lifestyle, fashion, food industry.

Tamburi Investment Partners S.p.A. is an Italian, independent investment-merchant bank focused on «excellent» companies (€ 1.4bn direct investments and club deals) – listed on FTSE MIB.

Facebook

Twitter

LinkedIn

Google Plus

Instagram

Contact